» Articles » PMID: 25553892

Characterization of TRIF Selectivity in the AGP Class of Lipid A Mimetics: Role of Secondary Lipid Chains

Overview
Specialty Biochemistry
Date 2015 Jan 3
PMID 25553892
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

TLR4 agonists that favor TRIF-dependent signaling and the induction of type 1 interferons may have potential as vaccine adjuvants with reduced toxicity. CRX-547 (4), a member of the aminoalkyl glucosaminide 4-phosphate (AGP) class of lipid A mimetics possessing three (R)-3-decanoyloxytetradecanoyl groups and d-relative configuration in the aglycon, selectively reduces MyD88-dependent signaling resulting in TRIF-selective signaling, whereas the corresponding secondary ether lipid 6a containing (R)-3-decyloxytetradecanoyl groups does not. In order to determine which secondary acyl groups are important for the reduction in MyD88-dependent signaling activity of 4, the six possible ester/ether hybrid derivatives of 4 and 6a were synthesized and evaluated for their ability to induce NF-κB in a HEK293 cell reporter assay. An (R)-3-decanoyloxytetradecanoyl group on the 3-position of the d-glucosamine unit was found to be indispensable for maintaining low NF-κB activity irrespective of the substitutions (decyl or decanoyl) on the other two secondary positions. These results suggest that the carbonyl group of the 3-secondary lipid chain may impede homodimerization and/or conformational changes in the TLR4-MD2 complex necessary for MyD88 binding and pro-inflammatory cytokine induction.

Citing Articles

Review: Current trends, challenges, and success stories in adjuvant research.

Singleton K, Joffe A, Leitner W Front Immunol. 2023; 14:1105655.

PMID: 36742311 PMC: 9892189. DOI: 10.3389/fimmu.2023.1105655.


Rational Vaccine Design in Times of Emerging Diseases: The Critical Choices of Immunological Correlates of Protection, Vaccine Antigen and Immunomodulation.

Schijns V, Majhen D, Van der Ley P, Thakur A, Summerfield A, Berisio R Pharmaceutics. 2021; 13(4).

PMID: 33917629 PMC: 8067490. DOI: 10.3390/pharmaceutics13040501.


Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection.

Hernandez A, Patil N, Stothers C, Luan L, McBride M, Owen A Pharmacol Res. 2019; 150:104502.

PMID: 31689522 PMC: 6884699. DOI: 10.1016/j.phrs.2019.104502.

References
1.
Duthie M, Windish H, Fox C, Reed S . Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011; 239(1):178-96. PMC: 5872835. DOI: 10.1111/j.1600-065X.2010.00978.x. View

2.
Kolumam G, Thomas S, Thompson L, Sprent J, Murali-Krishna K . Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005; 202(5):637-50. PMC: 2212878. DOI: 10.1084/jem.20050821. View

3.
Lam C, SCHUTZE E, Hildebrandt J, Aschauer H, Liehl E, Macher I . SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother. 1991; 35(3):500-5. PMC: 245039. DOI: 10.1128/AAC.35.3.500. View

4.
Stover A, da Silva Correia J, Evans J, Cluff C, Elliott M, Jeffery E . Structure-activity relationship of synthetic toll-like receptor 4 agonists. J Biol Chem. 2003; 279(6):4440-9. DOI: 10.1074/jbc.M310760200. View

5.
Garidel P, Rappolt M, Schromm A, Howe J, Lohner K, Andra J . Divalent cations affect chain mobility and aggregate structure of lipopolysaccharide from Salmonella minnesota reflected in a decrease of its biological activity. Biochim Biophys Acta. 2005; 1715(2):122-31. DOI: 10.1016/j.bbamem.2005.07.013. View